REFERENCES
- Stoll BJ, Gordon T, Korones SB et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal research Network. J Pediatr 1996; 129: 63–71.
- Khadilkar V, Tudehope D, Fraser S. A prospective study of nosocomial infection in a neonatal intensive care unit. J Paediatr Child Health 1995; 31: 387–391.
- Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL. Necrotizing enterocolitis in very low birth weight infants: biodemographic and clinical correlates. J Pediatr 1991; 119: 630–8.
- De Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973–8.
- Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999; 281: 67–71.
- Struelens MJ, Byl B, Vincent JL. Antibiotic policy: a tool for controlling resistance of hospital pathogens. Clin Microbiol Infect 1999; 5: S19–S24.
- Hebra A, Ross AJ. Necrotizing enterocolitis. In: Spitzer AR, ed. Intensive care of the fetus and neonate. 1st ed. St. Louis: Mosby. 1996: 865–874.
- Sanders WE, Sanders CC. Piperacillin/Tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996; 22: 107–123.
- Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP. Safety profile of piperacillin/tazobactam in phase I and III clin-ical studies. J Antimicrob Chemother 1993; 31, Suppl. A: 113-124.
- Arguedas A, Sifuentes-Osornio J, Loaiza C, Herrera M, Corrales JC, Mohs E. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. J Chemother 1996; 8: 130–6.
- Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella Pneumoniae infections in neonates. Am J Perinatol 1998; 15: 47–51.
- Ntirnberger W, Bönig H, Burdach S, Göbel U. Tolerability of piperacillin/ tazobactam in children and adoles-cents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 1998; 26: 65–7.
- Bell MJ, Ternberg JL, Feigin RD et al. Neonatal necro-tizing enterocolitis: therapeutic decision based upon clinical staging. Ann Surg 1978; 187: 1–7.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 11th informational supplement M100-S11. Wayne, PA, 2001.
- Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single-Dose Pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994; 38: 2817–26.